{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Raghav K"],"funding":["NCI NIH HHS"],"pagination":["472-478"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9870237"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["41(3)"],"pubmed_abstract":["<i>Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in</i> JCO <i>or elsewhere, for which the primary end point has already been reported.</i>Acquired genomic alterations (Acq-GAs), specifically <i>RAS</i>, <i>BRAF</i>, and <i>EGFR</i>-ectodomain mutations and <i>ERBB2</i> and <i>MET</i> amplifications, are recognized as major mechanisms of resistance to later-line anti-EGFR-antibody therapy in metastatic colorectal cancer (mCRC). However, data regarding emergence of these Acq-GAs under the selective "],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance)."],"pmcid":["PMC9870237"],"funding_grant_id":["U10 CA180882","U10 CA180819","U10 CA180830","UG1 CA233329","R01 CA184843","UG1 CA180830","U24 CA196171","U10 CA180821","U10 CA180888"],"pubmed_authors":["Kopetz S","Lenz HJ","Sun R","Raghav K","Innocenti F","Ou FS","Venook AP"],"additional_accession":[]},"is_claimable":false,"name":"Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).","description":"<i>Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in</i> JCO <i>or elsewhere, for which the primary end point has already been reported.</i>Acquired genomic alterations (Acq-GAs), specifically <i>RAS</i>, <i>BRAF</i>, and <i>EGFR</i>-ectodomain mutations and <i>ERBB2</i> and <i>MET</i> amplifications, are recognized as major mechanisms of resistance to later-line anti-EGFR-antibody therapy in metastatic colorectal cancer (mCRC). However, data regarding emergence of these Acq-GAs under the selective ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-22T03:12:02.774Z","creation":"2025-04-05T20:40:05.397Z"},"accession":"S-EPMC9870237","cross_references":{"pubmed":["36067452"],"doi":["10.1200/JCO.22.00365"]}}